Joint (NASDAQ:JYNT) Share Price Crosses Above Fifty Day Moving Average – What’s Next?

The Joint Corp. (NASDAQ:JYNT) crossed above its fifty day moving average during trading on Friday . The stock has a fifty day moving average of $8.95 and traded as high as $10.06. Joint shares last traded at $10.05, with a volume of 46,733 shares changing hands.

Analyst Ratings Changes

Several analysts have recently commented on the company. Weiss Ratings restated a “sell (e+)” rating on shares of Joint in a research note on Thursday. B. Riley lowered Joint from a “buy” rating to a “hold” rating in a report on Friday, November 7th. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Joint has a consensus rating of “Hold” and an average target price of $17.00.

Joint Trading Up 0.8%

The firm has a market capitalization of $149.44 million, a PE ratio of -167.47 and a beta of 1.29. The business has a 50-day moving average of $8.95 and a 200 day moving average of $9.57.

Joint (NASDAQ:JYNT) last posted its earnings results on Friday, November 7th. The company reported $0.02 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.01) by $0.03. Joint had a negative net margin of 1.78% and a negative return on equity of 0.98%. The firm had revenue of $13.38 million during the quarter, compared to analyst estimates of $13.36 million. On average, sell-side analysts expect that The Joint Corp. will post 0.11 EPS for the current fiscal year.

Insider Buying and Selling at Joint

In other Joint news, major shareholder Charles E. Jobson bought 13,000 shares of Joint stock in a transaction dated Monday, December 1st. The stock was bought at an average cost of $8.41 per share, with a total value of $109,330.00. Following the completion of the acquisition, the insider directly owned 1,605,027 shares in the company, valued at approximately $13,498,277.07. The trade was a 0.82% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In the last quarter, insiders purchased 38,251 shares of company stock valued at $325,109. 27.90% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of JYNT. O Brien Greene & Co. Inc boosted its stake in Joint by 33.6% in the second quarter. O Brien Greene & Co. Inc now owns 166,460 shares of the company’s stock worth $1,921,000 after buying an additional 41,840 shares in the last quarter. Stoneridge Investment Partners LLC bought a new stake in shares of Joint in the 3rd quarter worth approximately $117,000. JCP Investment Management LLC purchased a new stake in shares of Joint in the 2nd quarter valued at $5,526,000. Topline Capital Management LLC boosted its stake in shares of Joint by 18.7% in the 2nd quarter. Topline Capital Management LLC now owns 449,204 shares of the company’s stock valued at $5,184,000 after purchasing an additional 70,910 shares in the last quarter. Finally, Geode Capital Management LLC grew its holdings in shares of Joint by 17.6% during the 2nd quarter. Geode Capital Management LLC now owns 345,330 shares of the company’s stock valued at $3,986,000 after purchasing an additional 51,704 shares during the last quarter. 76.88% of the stock is owned by institutional investors.

Joint Company Profile

The Joint Chiropractic, Inc, doing business as Joint (NASDAQ: JYNT), is a franchisor and operator of outpatient chiropractic clinics in the United States. Under its flagship The Joint Chiropractic brand, the company offers membership-based, cash-focused spinal adjustment services designed to promote accessible, routine care for neck and back discomfort. By removing insurance requirements and offering walk-in visits, Joint aims to streamline the patient experience and reduce cost barriers to ongoing chiropractic treatment.

Joint’s growth strategy centers on partnering with franchisees to expand its network of clinics.